Life Science Investors Converge on RESI Europe: Meet the Early Stage Therapeutics Panelists

14 Feb

By Lucy Parkinson, VP of Investor Research, LSN

LSN’s one overriding message is that entrepreneurs need to look globally for capital. That’s the ethos that guides RESI, and our Investor Research team maintain a network of investors based all over the world that regularly attend our RESI partnering events to meet with emerging CEOs. RESI’s first ever event in Europe is already attracting a high level of investor interest – Click here to see some of the firms that are confirmed to attend RESI Europe to look for early stage opportunities. Due to RESI’s laser focus on investment, there’s no more efficient way to connect with global capital – entrepreneurs can book up to 16 investor meetings in one day, and RESI’s unique partnering system helps get their messages to the most relevant investors in their space.

In addition to meetings, RESI provides two tracks of investor panels that help entrepreneurs understand how life science investors think, what they’re looking for, and what makes a deal go or no-go for them. RESI’s Early Stage Therapeutics panel will cover all these issues and more for biotech entrepreneurs. The participants are:

Sara Secall (Investment Director, Inveready Asset Management)

Sara is responsible for building the Biotech Portfolio. She led the negotiation of ZIP Solutions license to a world top-3 bioprocessing company based in Germany which led to ZIP Solutions’ sale to Bionaturis. She sits at the board of Agrasys, Avizorex, BDI, Innoup Pharma, Leukos, Oncostellae, VLP and is a Board Observer at Edesa Biotech. She worked for Chevron Technology Ventures, the corporate Venture Capital group based in California with USD 210 MM under management. As Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology start ups and she negotiated numerous technology licenses. She has worked extensively in the USA, Latin America and Europe. Sara holds a BS in Chemistry, MSc from Indiana University and an MBA from the London Business School.

Marco Boorsma (Partner, Forbion)

Marco is Partner at Forbion Capital Partners and joined the firm in 2007. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion Marco was Business Development Director and project manager at DSM Pharmaceutical Products and scientist at Cytos Biotechnology in Switzerland. He serves on the Board of Directors of Inflazome, NorthSea Therapeutics, Milestone Pharmaceuticals, Escalier Biosciences, RSPR Pharma, and Engene. After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Harvey Gross (Partner, Apollo Ventures)

Harvey is a Partner at Apollo Ventures, a life science venture capital firm and life science company builder working across Europe and North America. At Apollo, Harvey is working on the meaningful and future focused topic of health and biomedicine to make a difference. At Apollo, Harvey combines his entrepreneurial spirit and enthusiasm for finance to assess business opportunities and assist portfolio companies with strategy and venture development. Before joining Apollo, Harvey worked at the investment bank Lazard, where he conducted M&A activities on both buy and sell side mandates. He was also one of the first employees at the FinTech startup N26, where he was responsible for talent acquisition and setting up the customer support function. During his studies he co-founded his first NGO and has launched two other tech startups. Harvey holds a degree in International Business with a major in Finance from Maastricht University.

Martin Pfister (Senior Investment Manager: Life Sciences, High-Tech Gründerfonds)

Dr. Martin Pfister joined the High-Tech Gründerfonds (HTGF) Medtech/LifeSciences team in Bonn in 2010. HTGF is the largest Seedfonds in Europe with about 900 Mio EUR under management and an active portfolio of about 260 technology-based portfolio companies, about 95 of which are in life sciences.


  • studied a combination of Medicine and Pharmacy in Germany and New York University, Medical School with a PhD in Immunology
  • Started his career in the hospital/laboratory
  • moved to the start-up life sciences world 18 years ago.
  • co-founded two companies in the molecular Dx field (VC backed, Exit) and healthcare services (privately owned, Exit 2018)
  • @ HTGF manages a portfolio of 13 life science companies including Biotech, Medtech and digital health
  • holds board member seat in 4 companies including clinical stage Biotech

Roel Bulthuis (Managing Director, INKEF Capital)

Roel Bulthuis is a Managing Director and head of the Healthcare investment team at INKEF Capital. Roel combines close to 20 years of experience across venture capital, pharma business development and M&A and healthcare investment banking. Prior to joining INKEF he served as SVP and Managing Director of M-Ventures which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global business development and M&A at Merck Serono and in the healthcare investment banking team at Fortis Bank. Roel is a Kauffman Fellow and passionate about continuously challenging the status quo. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: